Article
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jan 2017
Ferrarotto Renata, Mitani Yoshitsugu, Diao Lixia, Guijarro Irene, Wang Jing, Zweidler-McKay Patrick, Bell Diana, William William N, Glisson Bonnie S, Wick Michael J, Kapoun Ann M, Patnaik Amita, Eckhardt Gail, Munster Pamela, Faoro Leonardo, Dupont Jakob, Lee J Jack, Futreal Andrew, El-Naggar Adel K, Heymach John V
Abstract excerpt
Purpose Adenoid cystic carcinomas (ACCs) represent a heterogeneous group of chemotherapy refractory tumors, with a subset demonstrating an aggressive phenotype. We investigated the molecular underpinnings of this phenotype and assessed the Notch1 pathway as a potential therapeutic target. Methods We genotyped 102 ACCs that had available pathologic and clinical data. Notch1 activation was assessed by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.